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Edited by Gerrit van MeerAbstract Receptor tyrosine kinases (RTKs) are transactivated
by the stimulation of G protein-coupled receptors (GPCRs).
Sphingosine 1-phosphate (S1P), a ligand of GPCR, is known as
a tumor-promoting lipid, but its signaling pathways are not fully
understood. We here demonstrated that S1P induces rapid and
transient tyrosine phosphorylation of epidermal growth factor
receptor (EGFR) and c-Met in gastric cancer cells, both of which
have been proposed as prognostic markers of gastric cancers.
The pathway of S1P-induced c-Met transactivation is Gi-
independent and matrix metalloproteinase-independent, which
diﬀers from that of EGFR transactivation. Our results indicate
that S1P acts upstream of various RTKs and thus may act as a
potent stimulator of gastric cancer.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Crosstalk between diﬀerent members of receptor families
has become a well-established concept in signal transduction.
Tyrosine phosphorylation of various receptor tyrosine kinases
(RTKs) in response to activation of many G protein-coupled
receptors (GPCRs), which was designated ‘‘transactivation’’,
has been shown to have important physiological conse-
quences and has drawn considerable attention in recent years.
Epidermal growth factor receptor (EGFR), HER2/neu,
platelet-derived growth factor b receptor (PDGFbR), insulin-
like growth factor-1 receptor, and vascular endothelial
growth factor (VEGF) receptors have been shown to be* Corresponding author. Fax: +81-3-3811-6822.
E-mail address: SHIDA-DIS@h.u-tokyo.ac.jp (D. Shida).
Abbreviations: EGF, epidermal growth factor; GPCR, G protein-
coupled receptor; HB-EGF, heparin-binding EGF-like growth factor;
HGF, hepatocyte growth factor; HUVEC, human umbilical vein
endothelial cell; LPA lysophosphatidic acid; MMP, matrix metallo-
proteinase; PTX, pertussis toxin; RTK, receptor tyrosine kinase; S1P,
sphingosine 1-phosphate; VEGF, vascular endothelial growth factor;
VSMC, vascular smooth muscle cell
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doi:10.1016/j.febslet.2004.10.024transactivated by various ligands of GPCRs [1–6]. One of the
most intensely studied pairs of receptors has been the RTK
for EGF and the GPCR for lysophosphatidic acid (LPA).
LPA, a natural phospholipid, is a potent mediator of a broad
range of cellular responses, including regulation of cell pro-
liferation, protection from apoptosis, and modulation of
chemotaxis [7–10]. Whereas LPA binds to three GPCRs,
LPA1/Edg-2, LPA2/Edg-4, and LPA3/Edg-7, it has been re-
ported that LPA utilizes, at least in part, EGFR as a
downstream signaling partner in many cell types. In various
human cancer cells, LPA-induced EGFR transactivation re-
sults in cell proliferation and motility, suggesting that LPA
plays an important role as a tumor promoter via EGFR
transactivation [11–14].
Sphingosine 1-phosphate (S1P), a structurally related lyso-
phospholipid, is a bioactive lipid mediator that is released in
large amounts from activated platelets [15]. S1P regulates
various cellular responses very similar to those induced by
LPA, while acting through distinct receptors [8]. Although
whether S1P acts intracellularly as a second messenger or
extracellularly as a receptor ligand, or both, is unknown,
exogenously added S1P binds to ﬁve GPCRs, S1P1/Edg-1,
S1P2/Edg-5, S1P3/Edg-3, S1P4/Edg-6, and S1P5/Edg-8. They
are ubiquitously expressed and coupled to various G proteins
that regulate numerous downstream signals. S1P1-knockout
mice exhibit intrauterine death owing to vascular abnormal-
ities, which indicates that S1P signaling is essential during
mammalian development [16]. S1P signaling is also linked to
diverse biological processes in human cancer, such as cell
proliferation and migration, and therefore S1P is now rec-
ognized as a tumor-promoting lipid [17–20]. Thus, the S1P
signaling pathway may have important functions in both
physiological and pathological conditions. Previous reports
have shown that S1P can also transactivate RTKs. For ex-
ample, exogenously added S1P transactivated EGFR in ﬁ-
broblasts and vascular smooth muscle cells (VSMC), but not
in human umbilical vein endothelial cells (HUVEC) [3,5,21].
S1P also transactivated PDGFbR in mouse embryonic ﬁ-
broblasts, VSMC, and ovarian and breast cancer cells, and
VEGF receptor, Flk-1/KDR and VEGFR2 in HUVEC
[3,5,22,23]. These results suggest that the transactivation by
S1P is dependent on cell types and possibly on S1P receptor
subtypes.
In the present study, using two gastric cancer cell lines, we
investigated whether S1P induces phosphorylation of twoblished by Elsevier B.V. All rights reserved.
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gression in gastric cancer [24–26].2. Materials and methods
2.1. Materials
S1P was purchased from Biomol (St. Louis, MO) and dissolved in
DMSO to 2 103 M, divided into aliquots and stored at )80 C.
Recombinant human hepatocyte growth factor (HGF) was purchased
from R&D Systems, Inc. (Minneapolis, MN). Rabbit polyclonal anti-
human c-Met antibody (C-28), rabbit polyclonal anti-human EGFR
antibody and mouse monoclonal anti-human phosphotyrosine anti-
body (PY20) were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Pertussis toxin (PTX) and the broad-spectrum
matrix metalloproteinase (MMP) inhibitor GM6001 were purchased
from Calbiochem (La Jolla, CA). An EGFR tyrosine kinase inhibitor
AG1478 was purchased from Biomol. Sphingomyelin, sphingosine,
and diphenyleneiodonium chloride were purchased from Sigma (St.
Louis, MO). The pyrazolopyridine derivative JTE-013, a speciﬁc S1P2
receptor antagonist, was a gift from the Central Pharmaceutical Re-
search Institute, Japan Tobacco Inc. (Osaka, Japan) [27].
2.2. Cell culture
The human gastric cancer cell lines MKN28 and MKN74 were
obtained from the Riken Cell Bank (Tsukuba, Japan). MKN28 and
MKN74 are cell lines established from moderately diﬀerentiated ade-
nocarcinomas. These cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal calf serum (Sigma), 100
U/ml penicillin, and 100 lg/ml streptomycin (Gibco BRL Co., Grand
Island, NY).Fig. 1. Rapid tyrosine phosphorylation of EGFR in response to S1P in
human gastric cancer cells. Human gastric cancer cells MKN28 and
MKN74 were serum-starved for 24 h and then stimulated for 2 min
with 1 lM S1P. After cell lysis, EGFR was immunoprecipitated (IP)
using polyclonal anti-EGFR antibody and immunoprecipitates were
immunoblotted with monoclonal anti-phosphotyrosine antibody. Cells
treated with 1 ng/ml EGF for 2 min were used as a positive control for
tyrosine phosphorylation. Then, the membrane was stripped and im-
munoblotted with anti-EGFR to detect EGFR at Mr 170 kDa, as a
control.2.3. Immunoprecipitation and western blot analysis
Immunoprecipitation and Western blot analysis were performed as
described previously [14,28]. In brief, MKN28 and MKN74 cells were
grown to 80–90% conﬂuence in 10 cm-dishes. These cells were starved
in serum-free medium for 24 h and then S1P was added to the culture
thereafter. After stimulation of starved cells with 1 lM S1P for various
times, cellular protein lysates (1 ml/dish/tube) were obtained and then
all proteins were incubated with antibodies against two RTKs, EGFR
and c-Met (20 ll/tube). Immunoprecipitates were collected with pro-
tein A–agarose. Immunoprecipitated proteins were electrophoresed in
sodium dodecyl sulfate (SDS)–7.5% polyacrylamide gel for 35 min at
200 V. Then, the protein was transferred onto an Immobilon transfer
membrane (Millipore Co., Bedford, MA) for sequential incubation
with 5% reconstituted non-fat milk powder to block non-speciﬁc sites,
dilutions of mouse monoclonal anti-phosphotyrosine antibody, and
then horseradish peroxidase-labeled sheep anti-mouse IgG, prior to
development with a standard ECL kit (Amersham, Inc., Bucking-
hamshire, England). Some cells were pretreated with 100 ng/ml PTX
for 24 h before stimulation and other cells were pretreated with 5–50
lM GM6001 for 30 min before stimulation. All membranes were
stripped and immunoblotted with antibodies against RTKs as a
control.
2.4. Preparation of total RNA and RT-PCR analysis
Total RNA was isolated fromMKN28 and MKN74 cells by the acid
guanidine isothiocyanate/phenol/chloroform extraction method as
described by Chomczynski and Sacchi [29]. Then, 1 lg of total RNA
was reverse-transcribed using a SuperScript First-Strand Synthesis
System (Invitrogen Co., Carlsbad, CA, USA). The primers used for the
RT-PCR analysis have been reported previously [30,31]. The sequences
of the primer used were as follows: S1P1 receptor (429-bp product),
sense, 50-TATCAGCGCGGACAAGGAGAACAG-30 and antisense,
50-ATAGGCAGGCCACCCAGGATGAG-30; S1P2 receptor (220-bp
product), sense, 50-TCGGCCTTCATCGTCATCCTCT-30 and anti-
sense, 50-CCTCCCGGGCAAACCACTG-30; S1P3 receptor (394-bp
product), sense, 50-CTGCCTGCACAATCTCCCTGACTG-30 and
antisense, 50-GGCCCGCCGCATCTCCT-30; glyceraldehydes-3-phos-
phate dehydrogenase (246-bp product), sense, 50-GATGACA
TCAAGAAGGTGGTGAA-30 and antisense, 50-GTCTTACT
CCTTGGAGGCCATGT-30. We ran 30 PCR cycles at 94 C (dena-
turation, 1 min), 62 C (annealing, 1 min), and 72 C (extension, 1min). PCR products were electrophoresed on a 2% agarose gel and
visualized by ethidium bromide staining.3. Results
3.1. S1P induced tyrosine phosphorylation of EGFR in gastric
cancer cells
We ﬁrst investigated whether S1P transactivates EGFR in
human gastric cancer MKN28 and MKN74 cells. These cells
were incubated with 1 lM S1P or 1 ng/ml EGF for 2 min and
examined for whether tyrosine phosphorylation of EGFR was
induced by S1P. As shown in Fig. 1, S1P induced signiﬁcant
tyrosine phosphorylation of EGFR in both MKN28 and
MKN74 cells.
3.2. S1P induced tyrosine phosphorylation of c-Met in gastric
cancer cells
The HGF receptor, c-Met, is also a member of RTKs, and
binding of HGF induces autophosphorylation of tyrosine
residues in c-Met. Recently, c-Met was reported to be trans-
activated by prostaglandin E2 (PGE2) in colon cancer cells, so
we hypothesized that S1P can transactivate c-Met [32]. Human
gastric cancer cells MKN28 and MKN74 were incubated with
1 lM S1P for 2–60 min, and examined for whether tyrosine
phosphorylation of c-Met was induced by S1P. As shown in
Fig. 2A, S1P induced signiﬁcant tyrosine phosphorylation of c-
Met in both MKN28 and MKN74 cells. Time course experi-
ments revealed that phosphorylation was maximal after 2–5
min of stimulation and declined thereafter, suggesting that S1P
induced rapid and transient tyrosine phosphorylation of c-
Met. A polyclonal antibody against c-Met was used to detect
p140c-met b-chain expression, as well as the 170c-met precursor.
The amount of c-Met immunoprecipitation was the same with
or without S1P (Fig. 2A). In reverse experiments, phosphoty-
rosine immunoprecipitation and anti-c-Met immunoblot re-
vealed the same results (Fig. 2B). Tyrosine phosphorylation of
c-Met induced by 1 lM S1P was as strong as that induced by 5
ng/ml HGF (Fig. 3).
3.3. Tyrosine phosphorylation of c-Met induced by S1P was not
inhibited by pertussis toxin
To elucidate the mechanism by which S1P transactivates c-
Met, we used several inhibitors. To address the question of
Fig. 3. Eﬀect of pertussis toxin, a Gi inhibitor, on S1P-stimulated c-
Met transactivation in gastric cancer cells. Human gastric cancer
MKN28 and MKN74 cells were serum-starved for 24 h with or
without 100 ng/ml PTX and then stimulated with 1 lM S1P or 5 ng/ml
HGF for 2 min. After cell lysis, c-Met was IP using anti-c-Met anti-
body. Immunoprecipitates were immunoblotted with anti-phosphoty-
rosine antibody. Then, the membrane was stripped and
immunoblotted with anti-c-Met as a control. The same experiments
were performed using anti-EGFR antibody as a control for the in-
hibitory eﬀect of PTX.
Fig. 2. Rapid tyrosine phosphorylation of c-Met in response to S1P in
human gastric cancer cells. (A) Human gastric cancer cells MKN28
and MKN74 were serum-starved for 24 h and then incubated with 1
lM S1P for 2–60 min. After cell lysis, c-Met was IP using polyclonal
anti-c-Met antibody and immunoprecipitates were immunoblotted
with monoclonal anti-phosphotyrosine antibody. Then, the membrane
was stripped and immunoblotted with anti-c-Met as a control. Anti-c-
Met antibody was used to detect the b-chain of the c-Met receptor at
Mr 140 kDa as well as its precursor form at Mr 170 kDa. (B) Human
gastric cancer cells MKN28 and MKN74 were serum-starved for 24 h
and then stimulated with 1 lM S1P for 2–10 min. These cell lysates
were immunoprecipitated with anti-phosphotyrosine antibody and
immunoprecipitates were immunoblotted with anti-c-Met antibody.
Fig. 4. Eﬀect of GM6001, an MMP inhibitor, on S1P-stimulated c-Met
transactivation in gastric cancer cells. Human gastric cancer cells
MKN28 and MKN74 were serum-starved for 24 h and pre-incubated
with the indicated concentrations of GM6001 for 30 min. After incu-
bation with 1 lM S1P for 2 min, cell lysates were obtained and IP with
anti-c-Met. Immunoprecipitates were immunoblotted with anti-phos-
photyrosine antibody. Then the membrane was stripped and immu-
noblotted with anti-c-Met as a control. The same experiments were
performed using anti-EGFR antibody as a control for the inhibitory
eﬀect of GM6001.
D. Shida et al. / FEBS Letters 577 (2004) 333–338 335whether a Gi-dependent mechanism is involved in S1P-induced
c-Met transactivation in gastric cancer cells, we examined the
eﬀect of PTX, a Gi inhibitor. As shown in Fig. 3, pretreatment
with PTX partly decreased the phosphorylation of EGFR in-
duced by S1P, which was compatible with previous reports on
VSMC [3]. In contrast, the phosphorylation of c-Met induced
by S1P was not altered by PTX pretreatment. Thus, S1P-in-
duced c-Met transactivation in gastric cancer cells seems to be
Gi-independent.
3.4. Tyrosine phosphorylation of c-Met induced by S1P was not
inhibited by GM6001
Previous reports have shown that GPCR-induced EGFR
transactivation requires MMP activation and cleavage of the
membrane-anchored growth factor precursor pro heparin-
binding EGF-like growth factor (HB-EGF) in COS-7, HEK-
293 cells and HNSCC [2,11]. As shown in Fig. 4, pretreatment
with the MMP inhibitor GM6001 decreased the phosphory-
lation of EGFR induced by S1P in a dose-dependent manner,
which was compatible with previous reports. To address the
question of whether such a ligand-dependent mechanism is
also involved in c-Met transactivation in gastric cancer cells,
we examined the eﬀect of GM6001. As shown in Fig. 4, in
contrast to EGFR transactivation, GM6001 did not signiﬁ-
cantly inhibit S1P-induced tyrosine phosphorylation of c-Met
at any concentration. Thus, S1P-induced c-Met transactivation
in gastric cancer cells does not require MMP activation.
3.5. S1P Induced tyrosine phosphorylation of both c-Met and
EGFR via S1P2 receptor in gastric cancer cells
We examined S1P-related molecules such as sphingomyelin
and sphingosine, in order to investigate whether this transac-
tivation is mediated by S1P receptor or by a direct eﬀect of S1P
on the plasma membrane. As shown in Fig. 5A, only S1P, but
not sphingomyelin or sphingosine, induced transactivation of
c-Met and EGFR, which suggests that transactivation of both
is mediated by S1P receptor. Therefore, we next analyzed the
mRNA expression of diﬀerent S1P receptors by RT-PCR, to
determine which isoforms of S1P receptor are expressed on
gastric cancer cells. As shown in Fig. 5B, both MKN28 and
MKN74 cells exclusively expressed the S1P2 receptor among
three major S1P receptors. We conﬁrmed the reliability of ourRT-PCR by using HUVEC as positive control for S1P1 and
S1P3, and also conﬁrmed that the RT-PCR product obtained
without the addition of reverse transcriptase did not contain a
DNA band in the gel (data not shown). We then examined the
eﬀect of JTE-013, a speciﬁc antagonist of the S1P2 receptor, on
transactivation induced by S1P. As shown in Fig. 5C, JTE-013
completely inhibited S1P-induced tyrosine phosphorylation of
c-Met as well as that of EGFR in both cells. This compound
did not inhibit HGF-induced tyrosine phosphorylation of c-
Met or EGF-induced tyrosine phosphorylation of EGFR in
gastric cancer cells (Fig. 5C). Taken together, these results
indicate that S1P induced both c-Met phosphorylation and
EGFR phosphorylation via S1P2 receptor in gastric cancer
cells.
3.6. S1P-induced c-Met transactivation is independent from
EGFR kinase activity in gastric cancer cells
Transactivation of c-Met induced by PGE2 was shown to be
dependent on EGFR kinase activity in colon cancer cells.
However, very recent report revealed that c-Met transactiva-
tion induced by LPA and thrombin was independent on
EGFR kinase activity in hepatocellular and pancreatic cancer
cells [32,33]. Therefore, we examined the eﬀect of an EGFR
Fig. 5. Involvement of S1P2 receptor with S1P-induced transactivation
in gastric cancer cells. (A) Human gastric cancer cells MKN28 and
MKN74 were serum-starved for 24 h and then stimulated for 2 min
with 1 lM sphingomyelin, 1 lM sphingosine, and 1 lM S1P. After cell
lysis, c-Met or EGFR was IP using polyclonal anti-c-Met or anti-
EGFR antibody, respectively, and immunoprecipitates were immu-
noblotted with monoclonal anti-phosphotyrosine antibody. Then, the
membrane was stripped and immunoblotted with anti-c-Met or anti-
EGFR as a control. (B) RT-PCR analysis was performed on mRNA
isolated from both MKN28 and MKN74 cells. (C) Human gastric
cancer cells MKN28 and MKN74 were serum-starved for 24 h and
then pre-incubated with 10 lM JTE-013 for 10 min. After incubation
with 1 lM S1P for 2 min, cell lysates were obtained and IP with anti-c-
Met or anti-EGF antibody. Immunoprecipitates were immunoblotted
with anti-phosphotyrosine antibody. Then, the membrane was stripped
and immunoblotted with anti-c-Met or anti-EGFR as a control.
Fig. 6. Eﬀect of AG1478, an EGFR tyrosine kinase inhibitor, on S1P-
stimulated c-Met transactivation in gastric cancer cells. Human gastric
cancer MKN28 and MKN74 cells were serum-starved for 24 h and
pre-incubated with 250 ng/ml AG1478 for 30 min. After incubation
with 1 lM S1P for 2 min, cell lysates were obtained and IP with anti-c-
Met. Immunoprecipitates were immunoblotted with anti-phosphoty-
rosine antibody. Then, the membrane was stripped and immunoblot-
ted with anti-c-Met as a control.
Fig. 7. Eﬀect of DPI, an NADPH oxidase-speciﬁc inhibitor, on S1P-
stimulated c-Met transactivation in gastric cancer cells. Human gastric
cancer cells MKN28 and MKN74 were serum-starved for 24 h and
then pre-incubated with 10 lM DPI for 30 min. After incubation with
1 lM S1P for 2 min, cell lysates were obtained and IP with anti-c-Met.
Immunoprecipitates were immunoblotted with anti-phosphotyrosine
antibody. Then, the membrane was stripped and immunoblotted with
anti-c-Met as a control.
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transactivation. Whereas AG1478 (250 nM) markedly inhib-
ited EGF-induced tyrosine phosphorylation of EGFR (data
not shown), it did not signiﬁcantly inhibit c-Met phosphory-
lation induced by S1P as well as HGF (Fig. 6). These results
suggest that S1P-induced c-Met transactivation was indepen-
dent from EGFR kinase activity in gastric cancer cells.
3.7. S1P-induced c-Met transactivation is mediated with
reactive oxygen species in gastric cancer cells
In a recent paper by Fischer et al. [33], the transactivation of
c-Met by both LPA and thrombin has been shown to be
mediated by reactive oxygen species (ROS). Thus, we exam-
ined the eﬀect of an NADPH oxidase-speciﬁc inhibitor, di-
phenyleneiodonium chloride (DPI). Because recent lines ofresearch implicated membrane-bound NADPH oxidases in the
growth factor stimulated production of ROS, DPI interferes
with NAPDH oxidase-dependent ROS production [33,34]. As
shown in Fig. 7, blockade of NADPH oxidase function abol-
ished c-Met phosphorylation induced by S1P in both cells,
whereas only marginally aﬀected c-Met phosphorylation in-
duced by HGF.4. Discussion
RTKs regulate many key processes, such as cell prolifera-
tion, diﬀerentiation, motility and survival. Dysregulation of
RTKs by mutation, gene rearrangement, gene ampliﬁcation,
and overexpression of both receptors and ligands has been
implicated as causative factors in the development and pro-
gression of numerous human cancers. Two RTKs, EGFR and
c-Met, serve as prognostic markers in human gastric cancer,
which indicate that both RTKs play an important role in
gastric cancer development and progression [24–26]. In this
study, we demonstrated that S1P transactivates EGFR and c-
Met in gastric cancer cells. This intercellular receptor cros-
stalk between S1P receptors and these two RTKs suggests
that S1P may be a potent stimulator of gastric cancer pro-
gression by acting upstream of various RTK signaling path-
ways (Fig. 8).
Sphingosine 1-phosphate
S1P2 receptorEGFR c-Met
“RTK transactivation”
Gastric cancer cells
Various cellular responses
Fig. 8. Summary of eﬀects of S1P on human gastric cancer cells.
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also integrate diverse stimuli such as LPA, bombesin, thrombin,
and S1P [1,2,5,6,21]. This transactivation of EGFR represents
the paradigm for cross-talk between GPCRs and RTK signal-
ing pathways. From this knowledge, a novel picture of EGFR
as a central cellular network element has been established in
recent years, which broadens both its physiological as well as
pathological signiﬁcance [35–37]. In gastric cancer, Helicobac-
ter pylori (H. pylori), a pathogenic Gram-negative bacterium
that colonizes human gastric mucosa, is known to induce
EGFR activation [38,39]. Since H. pylori infection has a strong
association with the development of gastric cancer, S1P as well
as other GPCR ligands may also be involved in the carcino-
genesis of gastric cancer via EGFR transactivation [40,41].
c-Met is another RTK that is overexpressed in many solid
tumors. HGF, the natural ligand for c-Met, induces auto-
phosphorylation of tyrosine residues in c-Met and can lead to
proliferation, increased survival, altered motility, and en-
hanced invasion into the extracellular matrix. Recently, c-Met
was shown to be transactivated by PGE2 in colon cancer cells,
which resulted in the promotion of colon cancer cell invasion
[32]. In this study, we revealed that S1P induced deﬁnite ty-
rosine phosphorylation of c-Met in gastric cancer cells
MKN28 and MKN74. We also revealed that tyrosine phos-
phorylation of c-Met induced by S1P was rapid and transient,
which is the same as that of EGFR.
Previous studies indicate that S1P-stimulated transactivation
of EGFR requires MMP activation, whereas S1P-stimulated
transactivation of both PDGFbR and VEGFR2 does not,
suggesting a diﬀerent pathway of RTK transactivation by S1P
[3,23]. In our study of gastric cancer cells, S1P-induced
transactivation of c-Met was not signiﬁcantly inhibited by
GM6001. These data suggest that c-Met transactivation by
S1P does not require MMP activation and that the pathway of
S1P-induced c-Met transactivation in gastric cancer cells seems
to diﬀer from that of EGFR transactivation. Since MMP ac-
tivation induced proteolytic cleavage of transmembrane pro-
HB-EGF, which subsequently activates EGFR, it seems
acceptable that c-Met as well as PDGFbR and VEGFR2 do
not have such transmembrane precursors [2].
It has been shown that both S1P-induced EGFR transacti-
vation and S1P-induced PDGFbR transactivation in VSMC
are Gi-dependent [3]. In contrast, transactivation of c-Met
induced by S1P in this study did not show inhibition by a Gi
inhibitor. This is a novel ﬁnding in this ﬁeld. Previous studiesof other GPCR ligands have shown that not only Gi, but also
Gq plays a role in EGFR transactivation [1,6,42]. In order to
investigate the possible role of Gq in c-Met transactivation by
GPCR ligands, we examined the eﬀect of bombesin, whose
receptor is known to couple with Gq. However, bombesin did
not induce the signiﬁcant phosphorylation of c-Met in gastric
cancer cells under any experimental conditions (data not
shown). It does not directly mean the negative contribution of
Gq to c-Met transactivation, since the expression level of
bombesin receptor is not characterized in these cells. Because
of the lack of a well-known inhibitor against Gq, we could not
obtain evidence for a role of Gq in S1P-induced c-Met trans-
activation.
We demonstrated that gastric cancer cells expressed S1P2
receptor, and that its antagonist JTE-013 totally abrogated
both c-Met and EGFR transactivation induced by S1P, sug-
gesting that S1P2 receptor mediates this transactivation. Pre-
vious reports have shown that S1P1 receptor or S1P3 receptor
mediated cross-talk between S1P receptor and PDGFR [22,43–
45]. Our results suggest the receptor speciﬁc cross-talk between
RTKs and GPCR.
Pai et al. [32] have reported that PGE2 transactivates c-Met
in a manner dependent on functional EGFR in colon cancer
cells. Others also reported that activated EGFR can phos-
phorylate and activate c-Met in thyroid cancer cells and he-
patocytes [46,47]. In clear contrast, Fischer et al. [33] have
recently reported that EGFR activity is not essential for c-Met
transactivation induced by LPA or thrombin. In this study, we
used AG1478 and found that S1P-induced c-Met transactiva-
tion was independent of EGFR kinase activity, which is
compatible with the report of Fischer et al. [33].
Finally, we revealed that S1P-induced c-Met transactivation
requires NAPDH oxidase activity. Plasma membrane-bound
NAPDH oxidases have previously been implicated in the acute
and rapid production of ROS in response to growth factor
treatment [33,34]. Taken together, our results indicate that c-
Met transactivation induced by S1P is mediated by ROS,
which is compatible with previous report on that induced by
LPA or thrombin [33].
In summary, this study demonstrates that S1P, at physio-
logical concentration, activates two RTKs, whose signals are
crucial for gastric cancer progression, although the mecha-
nisms are somewhat diﬀerent. Gastric cancers are often asso-
ciated with local bleeding and thus, at the tumor site, platelets
are activated and release various growth factors including S1P.
Therefore, a signiﬁcant amount of extracellular S1P is thought
to be present in gastric cancer tissue and thus able to induce
various important biological responses. The development of an
antagonist for S1P or the appropriate spectrum of S1P re-
ceptors may also be new and eﬀective therapy for gastric
cancer.
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